-
![David Younger_A-Alpha Bio]( "CEO Q&A: David Younger, Ph.D.")
CEO Q&A: David Younger, Ph.D.1/5/2024Life Science Leader catches up with David Younger, co-founder and CEO of A-Alpha Bio, about the promise of molecular glues, the challenges of starting up a new company, and collaborating with Big Pharma.
-
![Tiffany_Olson_Color_Print-2 (1)]( "Ahead Of The Curve On Radiopharmaceuticals")
Ahead Of The Curve On Radiopharmaceuticals1/1/2024Former president of Cardinal Health’s nuclear and precision health solutions group Tiffany Olson discusses her work on Bayer's Xofigo, and how she anticipated the rise of radiopharmaceuticals.
-
![Ben Comer_450x300]( "A New Year At Life Science Leader")
A New Year At Life Science Leader1/1/2024Life Science Leader wishes you a happy New Year and announces plans for 2024.
-
![Steve Paul_CEO, Karuna Therapeutics]( "Where Are They Now? Karuna Therapeutics")
Where Are They Now? Karuna Therapeutics1/1/2024A new series from Life Science Leader looks backward, and forward, at the biopharmaceutical companies that have previously appeared in the pages of Life Science Leader magazine.
-
![Finance450x300]( "Finance And Funding Outlook 2024: Additional Responses")
Finance And Funding Outlook 2024: Additional Responses12/14/2023Additional 2024 Outlook responses from biopharma leaders on finance and funding topics.
-
![Ben Comer_450x300]( "Leadership For Tomorrow")
Leadership For Tomorrow12/1/2023Biopharma heavy hitters convened at the Galien Forum in New York City, offering tips and guidance for the leaders of tomorrow.
-
![EXECUTIVE OUTLOOK_450x300]( "Executive Outlook: Converting Innovative Science Into Predictable Returns")
Executive Outlook: Converting Innovative Science Into Predictable Returns12/1/2023Executives at Big Pharma and small biotech will be rewarded in 2024 if they can find new ways to develop and commercialize drugs in the context of an unforgiving investment, payer, and regulatory landscape.
-
![Finance450x300]( "Finance And Funding: Anticipating Improvement, Planning For Uncertainty")
Finance And Funding: Anticipating Improvement, Planning For Uncertainty12/1/2023Executives responding to this year’s finance and funding outlook questions are optimistic about the potential for a turnaround in 2024.
-
![MANUFACTURING_450x300]( "Manufacturing And Supply Chain: Making Space Between A Rock And A Hard Place")
Manufacturing And Supply Chain: Making Space Between A Rock And A Hard Place12/1/2023Biopharmaceutical companies can’t afford to halt production lines due to manufacturing violations next year. Manufacturing and supply chain processes will require fresh thinking and flexibility in 2024.
Ben Comer
Ben Comer is chief editor of Life Science Leader magazine. He has covered the biopharmaceutical, medtech and medical device industries for 15 years as a reporter and editor, and worked as a senior manager in PwC’s Health Research Institute. Comer was most recently executive editor at In Vivo magazine, where he wrote feature stories, executive profiles and articles ranging from pre-clinical biotech strategy, fundraising, supply chain, manufacturing, and regulatory issues, to global commercialization efforts, market access and environmental, social and governance topics. He has interviewed hundreds of executives and experts at biopharmaceutical and life science companies, academic institutions, law firms, patient advocacy groups, payer and provider organizations, industry trade associations and regulatory bodies. Comer has presented and moderated panels at dozens of industry conferences, convened webcasts with industry leaders, and published news articles and other writing in Scrip, Pink Sheet, MedTech Insight, Generics Bulletin, Pharmaceutical Executive, PharmTech, Applied Clinical Trials, Medical Marketing & Media and PR Week, among others. Comer is a graduate of the College of Charleston and has worked in compounding pharmacies as a certified technician. You can find him on Twitter @BenMComer.